Cancer cells

King’s College to trial innovative liquid radiotherapy for cancer in UK first

King’s College Hospital have begun a phase 4 clinical trial investigating the effectiveness of “liquid radiotherapy” for patients with skin cancer, becoming the first centre in the UK to do so.

The EPIC-Skin study is evaluating the use of rhenium radionuclide therapy against non-melanoma skin cancer – the UK sees almost 150,000 new cases of non-melanoma skin cancer every single year, with more than 7.7 million recorded globally.

As part of the innovative one-off treatment, clinicians will position a barrier material, similar to cling film, on the cancerous lesion. Liquid radiotherapy is then applied to the lesion, penetration both the material and skin targeted beneath.

The standard treatment for this type of cancer is surgical removal, which risks scarring and loss of function. Rhenium radionuclide therapy however, protects neighbouring healthy tissue by using a non-invasive paste that contains beta-emitting particles that target the cancer cells directly.

The new treatment will only be used on patients for who conventional treatment is unsuitable or have had recurrent issues with non-melanoma skin cancer.

Dr Nicola Mulholland, Consultant Nuclear Medicine Physician at King’s College Hospital and study Chief Investigator, said: “With rates of non-melanoma skin cancer on the rise globally, it is vitally important that new treatments are developed and tested. We are very pleased to be able to offer new therapies to patients involved in studies and trials, with the hope of advancing treatment for skin cancer."

Researchers will evaluate patients at study centres across Australia, Austria and Germany, as well as adult patients at King’s, where their progress will be monitored for approximately two years to see how well the treatment is working, and determine any possible side effects.

Dr Saqib Bashir, Consultant Dermatologist and Skin Cancer Lead at King's College Hospital, said: “When it comes to cancer research, it’s important to continually innovate. This study offers an opportunity to further investigate the efficacy of non-invasive epidermal radioisotope therapy.”

As well as testing its efficacy, the EPIC-Skin trial will also monitor things like patient quality of life, cosmetic impacts, and treatment comfort.

National Health Executive, Nov/Dec, Cover

NHE Nov/Dec 22

How active travel can help staff save money, improve wellbeing and help meet net zero targets

This issue highlights the latest topics within the health sector, from the NHS outlining its net zero strategy, Virtual hospitals, sustainable healthcare, How the NHS can achieve financial stability and more with articles featuring industry leaders such as Rory Deighton, Acute Network Director for NHS Confederation, Dr Tom Milligan, Clinical Lead for Diabetes in Humber and North Yorkshire, Misha Garcia, Value Programme Lead, NHS Property Services and many more.


View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Events

NHE has created a full calendar of events to address the most important issues that influence the delivery of healthcare services. Over 365 days you'll have the opportunity to hear from a range of highly motivating, informative and inspirational speakers. These speakers will equip you with the knowledge and unique insight to enable you to overcome the challenges that you face.

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all